

**CAUSATIVE ORGANISMS, ANTIBIOTIC SENSITIVITY PATTERNS AND  
RISK FACTORS ASSOCIATED WITH NEONATAL SEPSIS AT MOI  
TEACHING AND REFERRAL HOSPITAL, KENYA**

**ATEKA, BENARD MAGETO**

**DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE  
REQUIREMENT FOR THE DEGREE OF MASTER OF MEDICINE CHILD  
HEALTH AND PEDIATRICS, MOI UNIVERSITY.**

**© 2021**

## DECLARATION

### **Student's declaration**

This thesis is my original work done during the Master of Medicine in Child Health and Pediatrics degree course of Moi University School of Medicine

Ateka, Benard Mageto

SM/PGCHP/02/13

Signature:..... Date.....

### **Supervisors' declaration**

This research thesis has been submitted for examination with our approval as University supervisors.

#### **Professor Winstone Nyandiko**

Associate Professor and Pediatrician,

Department of Child Health and Pediatrics,

Moi University.

Signature:..... Date.....

#### **Dr. Julia Songok**

Lecturer and Pediatrician,

Department of Child Health and Pediatrics,

Moi University.

Signature:..... Date.....

## **ACKNOWLEDGEMENT**

My sincere thanks to my supervisors Professor Winstone Nyandiko and Dr. Julia Songok for their professional guidance throughout the study.

Many thanks to the biostatistician for his profound assistance with the statistical and analysis aspect of this study. I acknowledge my post-graduate colleagues and staff in the Pediatrics, Laboratory and Records departments of Moi Teaching and Referral Hospital, Kenya. Lastly, but not least, I thank my family members for encouragement, support and prayers throughout my entire study period.

## TABLE OF CONTENTS

DECLARATION .....	ii
ACKNOWLEDGEMENT .....	iii
TABLE OF CONTENTS.....	iv
LIST OF TABLES .....	vii
ABBREVIATIONS AND ACRONYMS .....	viii
OPERATIONAL DEFINITIONS.....	ix
ABSTRACT.....	xi
CHAPTER ONE .....	1
1.0 INTRODUCTION .....	1
1.1 Background information .....	1
1.2 Problem Statement .....	4
1.3 Justification .....	4
1.4 Research Question.....	5
1.5 Objective .....	5
1.5.1 Broad Objective.....	5
1.5.2 Specific Objectives .....	5
CHAPTER TWO .....	6
2.0 LITERATURE REVIEW .....	6
2.1 Causative Organisms of Neonatal Sepsis.....	6
2.2 Antibiotic Sensitivity Patterns of Organisms Causing Neonatal Sepsis .....	7
2.3 Risk Factors for Neonatal Sepsis .....	9
CHAPTER THREE .....	12
3.0 METHODOLOGY .....	12
3.1 Study design .....	12
3.2 Study site .....	12
3.3 Target population .....	13
3.4 Study population .....	13
3.4.1 Inclusion criteria.....	13
3.4.2 Exclusion criteria:.....	13
3.5 Study period .....	13
3.6 Sample Size.....	13

3.7 Study Procedure and Data Collection Techniques .....	14
3.7.1 Sampling Technique .....	14
3.7.2 Study Procedure.....	14
3.8 Data Analysis and Presentation.....	15
3.9 Ethical considerations .....	16
CHAPTER FOUR.....	17
RESULTS .....	17
4.0 Description of Study Participants.....	17
4.1 Causative organisms of bacterial neonatal sepsis at Moi Teaching and Referral Hospital’s newborn unit. ....	19
4.2 Antibiotic sensitivity patterns of organisms causing neonatal sepsis at Moi Teaching and Referral Hospital newborn unit. ....	20
4.3 Risk factors for neonatal sepsis at Moi Teaching and referral Hospital Newborn unit.....	22
CHAPTER FIVE .....	24
DISCUSSION .....	24
5.0 Introduction .....	24
5.1 Causative organisms of bacterial neonatal sepsis at Moi Teaching and Referral Hospital’s newborn unit. ....	24
5.2 Antibiotic sensitivity of organisms causing neonatal sepsis at Moi Teaching and Referral Hospital newborn unit.....	26
5.3 Risk factors for neonatal sepsis at Moi Teaching and referral Hospital Newborn unit.....	27
5.3.1 Maternal Risk Factors and Occurrence of Neonatal Sepsis .....	27
5.3.2 Neonatal Risk Factors and Occurrence of Neonatal Sepsis .....	28
CHAPTER SIX.....	30
6.0 CONCLUSIONS, RECOMMENDATIONS AND STUDY LIMITATIONS .....	30
6.1 Conclusions:.....	30
6.2 Study Recommendations:.....	30
6.3 Study Limitations .....	30

REFERENCES .....	31
APPENDICES .....	36
APPENDIX I: PARENTAL INFORMED CONSENT FORM.....	36
APPENDIX II: DATA COLLECTION TOOL .....	38
APPENDIX III: ETHICAL APPROVAL.....	40
APPENDIX IV: HOSPITAL APPROVAL (MTRH) .....	41

**LIST OF TABLES**

Table 1: Neonatal Characteristics .....	17
Table 2: Characteristics of participants' Mothers .....	18
Table 3: Frequency of Bacterial Isolates at MTRH Neonatal Unit .....	19
Table 4: <i>Klebsiella spp</i> Antibiotic Sensitivity and Resistance Patterns (N=70).....	20
Table 5: <i>Coagulase Negative Staphylococcus</i> (CoNS) antibiotic sensitivity and resistance (N=42) .....	21
Table 6: Neonatal Risk factors associated with Neonatal Sepsis. ....	22
Table 7: Maternal Risk Factors Associated with Neonatal Sepsis .....	23

**ABBREVIATIONS AND ACRONYMS**

<b>AOR</b>	Adjusted Odds Ratio
<b>CRP</b>	C - Reactive Protein
<b>GBS</b>	Group B streptococcus
<b>IREC</b>	Institutional Research and Ethics Committee
<b>IQR</b>	Interquartile range
<b>LOS</b>	Late onset neonatal sepsis
<b>MTRH</b>	Moi Teaching and Referral Hospital
<b>NBU</b>	Newborn Unit
<b>NICU</b>	Neonatal Intensive Care Unit
<b>OR</b>	Odds Ratio
<b>SPSS</b>	Statistical Package for Social Sciences
<b>WHO</b>	World Health Organization



## OPERATIONAL DEFINITIONS

- **Neonatal sepsis:** A clinical syndrome in an infant 28 days of age or younger, manifesting by systemic signs of infection and/or isolation of a bacterial pathogen from the blood stream.
- **Term infant:** Infant born at a gestational age of 37 or more completed weeks
- **Preterm infants:** Infant born at less than 37 weeks of gestation
- **Causative organisms:** Micro-organisms isolated during the course of an infection
- **Early-onset neonatal sepsis (EOS):** Neonatal sepsis with onset of symptoms at the age of 72 hours or earlier.
- **Late-onset neonatal sepsis (LOS):** Neonatal sepsis with onset of symptoms after the age of 72 hours.
- **Antibiotic sensitivity:** Susceptibility of bacterial (micro)organisms to antimicrobials.
- **Antibiotic susceptibility testing (AST):** Laboratory testing carried out on cultured bacteria (isolate) to determine the effectiveness of an antimicrobial to check or inhibit bacterial growth.

## ABSTRACT

**Background:** Neonatal sepsis is a clinical syndrome characterized by systemic signs of infection which can be confirmed by blood culture testing. Previous studies have reported high incidences of hospital associated sepsis; antimicrobial resistance coupled with increased mortality especially in the developing economies. There are limited local studies regarding antibiotic sensitivity patterns and its associated risk factors of neonatal sepsis. This limits empirical antibiotic therapy and local infection control strategies.

**Objectives:** To determine the causative organisms, antibiotic sensitivity patterns and risk factors associated with neonatal sepsis at Moi Teaching and Referral Hospital (MTRH) newborn unit.

**Methodology:** A cross-sectional study among 141 neonates with confirmed sepsis receiving care at MTRH new-born unit between September 2017 and July 2018. The participants were sampled consecutively until the desired sample size was achieved. Neonatal clinical characteristics were obtained from the participants' medical records while blood culture samples were collected for antimicrobial susceptibility testing. Data on maternal characteristics were obtained using an interviewer administered questionnaire. Descriptive statistics, Pearson chi-square test of association and odds ratios were conducted using statistical package for social sciences (SPSS) version 24.

**Results:** Females accounted for 57.4% of the 141 neonates enrolled. The median gestational age and birth weight were 37 (IQR: 22-45) weeks and 2400g (IQR: 800 - 4700) respectively; 78% (n=110) of the neonates were born via spontaneous vertex delivery. A total of 151 bacterial isolates were identified, majority (46.4%; n=70) being *Klebsiella pneumoniae*. followed by *Coagulate negative staphylococcus aureus* (CoNS) 27.8% (n=42). *Klebsiella pneumoniae* was sensitive to meropenem (OR=3.298; 95% CI: 2.219-4.902; p<0.001) and amikacin (OR=1.116; 95% CI: 0.920, 1.354; p=0.270). but resistant to vancomycin (OR=2.455; 95% CI:1.888-3.192; p<0.001), CoNS was sensitive to vancomycin (OR=5.710; 3.478-9.374; p<0.001) but resistant to the rest. Both the neonatal (mode delivery, place of birth, prematurity and 5-minute APGAR score) and maternal (parity, intrapartum pyrexia, age, level of education and urinary tract infection during pregnancy) risk factors showed no significant associations with the occurrence of neonatal sepsis.

**Conclusion:** The main bacterial causes of neonatal sepsis were *Klebsiella pneumoniae* and CoNS. Both the gram positive and gram-negative bacteria had good sensitivity to meropenem and amikacin. The risk factors evaluated were not associated with the occurrence of neonatal sepsis.

**Recommendations:** *Klebsiella pneumoniae* being one of the known nosocomial infections, improvement in infection control in the unit is recommended. There is need for evidence-based review of empirical antibiotic therapy regimen containing penicillin, gentamicin, and ceftriaxone due to the prevailing high resistance levels. Future larger studies designed to identify other risk factors for neonatal sepsis should be conducted.

## CHAPTER ONE

### 1.0 INTRODUCTION

#### 1.1 Background information

Neonatal sepsis is a clinical syndrome in an infant aged 28 days or less that manifests by systemic signs and symptoms of infection. It is a major cause of neonatal morbidity and mortality worldwide especially in the developing countries (Shane and Stoll 2014) . Previous epidemiological studies have reported infections as the leading cause of neonatal morbidity and mortality globally (Kang et al. 2011). Neonatal mortality rate in the developed economies is estimated at 0.69 deaths per 1000 live births which is lower than that of developing nations at 0.76 deaths per 1000 live births (Irshad and Hayat 2019). In a systematic review conducted on neonatal sepsis globally, it was reported that approximately 22 neonates per 1000 live births develop sepsis of which 11%-19% of them succumb to the disease (Fleischmann-Struzek et al. 2018). In Europe, a hospital incidence rate of 50 cases per 1000 neonatal unit admissions was reported in Greece (Gkentzi et al. 2019), while in the United Kingdom 49 per 1000 neonatal unit admissions was seen (Cailes et al. 2018). The mortality rate due to neonatal sepsis was estimated at 12% in Nigeria (Shobowale et al. 2017) and 28% in Kenya (Muthwii et al. 2019). Of the 30 million neonates who contract infections annually around the globe, approximately 2 million succumb to neonatal sepsis (Irshad and Hayat 2019).

Neonatal sepsis is caused by bacteria that is classified as either gram-positive or gram-negative based on their gram staining patterns. It can be confirmed by isolating the causative pathogen(s) from the bloodstream of the affected individual (Shane, Sánchez, and Stoll 2017). In the developing countries, gram-positive organisms (*Coagulase negative staphylococcus*-CoNS, *Enterococcus faecalis*, methicillin-

resistant and methicillin-susceptible *Staphylococcus aureus*- MRSA/MSSA and *Streptococcus pneumoniae*) are the predominant causative organisms (Shrestha et al. 2018). Gram-negative bacteria (*Klebsiella pneumoniae*, *Serratia marcescens*, *Acinetobacter baumannii* and *Escherichia coli*) have been associated with neonatal sepsis in developed countries (Sivanandan, Soraisham, and Swarnam 2011). In the developing countries, *Klebsiella* is the main causative organism of most neonatal sepsis while CoNS has been associated with sepsis in developed countries (Muller-Pebody et al. 2011).

In the Gulf states region of Kuwait, Saudi Arabia and United Arab Emirates, *Klebsiella spp.* and *Enterobacter spp.* were found to be sensitive to third generation cephalosporins such as cefotaxime and ceftriaxone (Hammoud et al. 2017). In the United Kingdom, early onset neonatal sepsis associated with gram negative bacteria has been reported to be susceptible to a combination of penicillin and gentamicin (94%), amoxicillin and cefotaxime (100%), amoxicillin and other penicillin (98%) and cefotaxime monotherapy at 96% (Muller-Pebody et al. 2011). However, a majority of the gram-positive bacteria resisted these treatment combinations. Cefotaxime was demonstrated not to be effective against *Enterococci spp.*, *Acinetobacter spp.* and *Listeria monocytogenes* while these late onset sepsis causing organisms are susceptible to gentamicin (Muller-Pebody et al. 2011). Frequent use of third generation cephalosporins drive the development of resistant bacterial pathogens in neonatal intensive care units with emergence of extended spectrum beta lactamase producing strains.

A combination of neonatal, maternal and environment risk factors predispose neonates to sepsis. Neonatal sepsis is classified, according to the time of onset of

symptoms, as either early onset where symptoms manifest earlier than 72 hours of life or late onset which manifests after 72 hours of life (Shane and Stoll 2014; Chacko and Sohi, n.d.; Y. Dong and Speer 2015; Y. Dong, Glaser, and Speer 2019). Early onset neonatal sepsis (EONS) is associated with causative factors (Abdellatif et al. 2019) of maternal origin and is often transmitted during antenatal period or labour (vertical transmission). Late onset neonatal sepsis (LONS) causative organisms are either community acquired or nosocomial among hospitalized neonates (Greenberg et al. 2017; Y. Dong, Glaser, and Speer 2019; H. Dong, Cao, and Zheng 2017). Most early onset neonatal sepsis is associated with both maternal and neonatal factors (Ramasethu and Kawakita 2017). Maternal factors include age of the mother, level of education, intrapartum pyrexia, parity, antenatal clinic attendance and presence of urinary tract infection during pregnancy (Shane and Stoll 2014; Gebremedhin, Berhe, and Gebrekirstos 2016). Neonatal risk factors include APGAR (appearance, pulse, grimace, activity and respiration) score, mode of delivery and maturity levels (Seale et al. 2014; Greenberg et al. 2017). Gram-positive organisms have been reported as the main causative organism for late onset neonatal sepsis (Hammoud et al. 2017). These gram-positive microbes could be from either exogenous or endogenous environmental factors (Legeay et al. 2015; Stockmann et al. 2014; Y. Dong, Speer, and Glaser 2018). The exogenous factors include the physical environment of birth and care which encompasses hygiene, medical equipment, procedures and traffic while endogenous factors include the flora of the patient (Stockmann et al. 2014).

## **1.2 Problem Statement**

Neonatal sepsis is one of the leading causes of morbidity and mortality among newborns globally (Kang et al. 2011; Obiero et al. 2015). Most of the neonates presenting with sepsis are likely to succumb to the disease if it is not promptly addressed. Its case mortality rate is higher in developing countries compared to the developed ones with an estimated prevalence of 12% and 28% in Nigeria (Shobowale et al. 2017) and Kenya (Muthwii et al. 2019) respectively. At a tertiary teaching hospital in Kenya, the rate of neonatal mortality attributed to sepsis was quite high among those born with a low birthweight (Njuguna, Kiptoon, and Nyandiko 2014). Although studies on neonatal sepsis have been conducted around the African continent, the major causative organisms of neonatal sepsis in Western Kenya as well as their antibiotic sensitivity patterns is not adequately documented. This is despite the fact that empirical data suggesting that a combination of neonatal, maternal and environment risk factors could predispose neonates to sepsis (Shane and Stoll 2014). This study therefore aimed at determining the causative organisms, antibiotic sensitivity patterns and risk factors associated with neonatal sepsis.

## **1.3 Justification**

There has been increasing reports of global antimicrobial resistance necessitating the institution of antibiotic stewardship (Shane and Stoll 2014; Shane, Sánchez, and Stoll 2017). In Kenya, neonates with multidrug resistant *K. pneumoniae* were reported not to respond to commonly used antibiotics such as third generation cephalosporins and gentamicin (Apondi et al. 2016). Identification of the causative organisms and their sensitivity patterns to commonly used antibiotics in the local setting will inform local infection control strategies. This is because there are limited local studies on antibiotic sensitivity patterns thus the need for profiling them to guide empirical therapy choice.

The risk factors for neonatal sepsis vary between geographic regions and demographic settings, thus necessitating more local studies. The findings from this study will inform policy makers on better treatment protocols for neonatal sepsis.

#### **1.4 Research Question**

What are the causative organisms, the antibiotic sensitivity patterns and risk factors of bacterial causes of neonatal sepsis at Moi Teaching and Referral Hospital?

#### **1.5 Objective**

##### **1.5.1 Broad Objective**

To determine the causative organisms, the antibiotic sensitivity patterns and risk factors associated with bacterial causes of neonatal sepsis at Moi Teaching and Referral Hospital newborn unit.

##### **1.5.2 Specific Objectives**

1. To determine the causative organisms of bacterial neonatal sepsis at Moi Teaching and Referral Hospital newborn unit.
2. To determine the antibiotic sensitivity of organisms causing neonatal sepsis at Moi Teaching and Referral Hospital newborn unit.
3. To determine risk factors associated with bacterial causes of neonatal sepsis at Moi Teaching and referral Hospital Newborn unit.

## CHAPTER TWO

### 2.0 LITERATURE REVIEW

Neonatal sepsis is a major cause of neonatal morbidity and mortality globally, with the greatest burden reported in the developing countries (Shane and Stoll 2014) . Approximately 6.7% of the neonates from around the world who contract sepsis annually succumb to the disease (Irshad and Hayat 2019).

#### 2.1 Causative Organisms of Neonatal Sepsis

Neonatal sepsis is caused by bacteria that is either gram-positive or gram-negative based on the gram staining patterns. In the developing countries, gram-positive organisms such as *Coagulase negative staphylococcus-CoNS*, methicillin-resistant and methicillin-susceptible *Staphylococcus aureus- MRSA/MSSA* and *Streptococcus pneumoniae*) are the predominant causes (Shrestha et al. 2018). Gram-negative bacteria such as *Klebsiella pneumoniae*, *Acinetobacter baumannii* and *Escherichia coli* have been associated with neonatal sepsis in developed countries (Sivanandan, Soraisham, and Swarnam 2011).

Neonatal sepsis (Irshad and Hayat 2019) is further classified according to the time of onset of symptoms as either early or late onset neonatal sepsis(Shane and Stoll 2014; Chacko and Sohi, n.d.; Y. Dong and Speer 2015; Y. Dong, Glaser, and Speer 2019). Early onset neonatal sepsis (EONS) is associated with causative factors (Abdellatif et al. 2019) of maternal origin and is often transmitted during labour or antenatally (vertical transmission). The most common bacterial causes of neonatal sepsis include: *Klebsiella spp*, *Escherichia coli*, *Staphylococcus aureus* and Group B streptococci (Downie et al. 2013). Late onset neonatal sepsis (LONS) causative organisms are either community acquired or nosocomial among hospitalized neonates (Greenberg et al. 2017; Y. Dong, Glaser, and Speer 2019; H. Dong, Cao, and Zheng 2017). The



causative organisms for LONS include *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Staphylococcus aureus*, Group B streptococcus and *Non-typhoidal salmonella* (Zaidi et al. 2009). In a systematic review on neonatal sepsis comprising of thirty four studies conducted around the globe, 20 studies reported that *Staphylococcus aureus* was the most common causative bacteria, followed by *Klebsiella pneumoniae* and *Escherichia coli* (Huynh et al. 2011). *Non-fermenting* gram-negative bacteria were the most isolated among neonates presenting with sepsis. *Staphylococcus aureus* was the most predominant among neonates with late onset neonatal sepsis (Sundaram, Kumar, and Narang 2009). However, studies in Tanzania (Blomberg et al. 2005; Mhada et al. 2012) found that early onset sepsis was primarily due to, *Staphylococcus aureus* and *Escherichia coli*, while late onset sepsis was due to *Klebsiella spp*, *Staph. aureus* and *Escherichia coli*. Group B streptococcus was isolated in blood culture tests from 11 studies (Blomberg et al. 2005; Mhada et al. 2012; Kiwanuka et al. 2013; Macharashvili et al. 2009; Mugalu, Nakakeeto, Kiguli, and Kaddu -Mulindwa 2006; Ojukwu et al. 2006; Sigauque et al. 2009; Talbert et al. 2010; Darmstadt, Batra, and Zaidi 2009; Mir et al. 2011; Gray 2007). Similarly in a retrospective analysis of blood cultures over an 11 year period conducted at the Moi Teaching and Referral Hospital in Kenya, *Klebsiella spp* was the predominant organism of neonatal sepsis at the newborn unit (Apondi et al. 2016).

## **2.2 Antibiotic Sensitivity Patterns of Organisms Causing Neonatal Sepsis**

Neonatal sepsis is caused by either gram-positive or gram-negative organisms. In Tanzania, 68% of *Klebsiella pneumoniae* and *Escherichia coli*, both gram-negative, were resistant to gentamicin and totally resistant (100%) to ampicillin (Mhada et al. 2012). The World Health Organization (WHO) recommended first line treatment for neonatal sepsis include penicillin (or ampicillin) and gentamicin combination. In the

event of staphylococcal infection, ampicillin is replaced by cloxacillin or flucloxacillin. The second line regimen include third generation cephalosporins such as ceftriaxone or cefotaxime. Antimicrobial susceptibility to *Klebsiella spp* to first line antibiotic regimen has been reported to be decreasing (Downie et al. 2013). The duration of antibiotic treatment may be influenced by the clinical status of the neonate, blood culture positivity and the pathogens isolated (Saini et al. 2011). In a systematic review of 12 studies on antibiotic resistance (Huynh et al. 2011), the authors reported resistance of gram-negative bacteria (excluding *Klebsiella spp.*) to penicillin/ ampicillin. *Klebsiella spp.* was reported to be 96% resistant to penicillin/ampicillin in Kenya (Talbert et al. 2010) and 100% resistant in Tanzania (Mhada et al. 2012). *Klebsiella* was further resistant to gentamicin (49% and 77%) and third generation cephalosporins (43% and 18%) in Kenya (Talbert et al. 2010) and Tanzania (Mhada et al. 2012) respectively.

More than half (55%) of *Escherichia coli* isolated in a study in Georgia (Macharashvili et al. 2009) and all (100%) of those isolated in Uganda (Mugalu, Nakakeeto, Kiguli, and Kaddu -Mulindwa 2006) resisted penicillin/ampicillin. In Kenya and Tanzania, *Escherichia coli* was resistant to penicillin in proportions of 78% (Talbert et al. 2010) and 93% (Mhada et al. 2012) respectively. There was no resistance to Gentamicin from gram negative bacteria (*Escherichia coli* and *Pseudomonas aeruginosa*) in Pakistan (Mir et al. 2011). The resistance of *Escherichia coli* to gentamicin was reported in Uganda at 29% (Mugalu, Nakakeeto, Kiguli, and Kaddu -Mulindwa 2006), Kenya at 10% (Talbert et al. 2010) and 43% in Tanzania (Mhada et al. 2012). *Escherichia coli* was not resistant to third generation cephalosporins in a study conducted in Malawi (Gray 2007); However, 6% (Mugalu,

Nakakeeto, Kiguli, and Kaddu -Mulindwa 2006) 17% (Talbert et al. 2010) and 14% (Mhada et al. 2012) resistance were reported in Uganda, Kenya and Tanzania respectively. *Staphylococcus aureus* was reported to be resistant to methicillin (a penicillin) in 67% of all the bacterial isolates in an Ethiopian study. In Kenya, *Acinetobacter baumannii* was resistant to penicillin at 56%, Gentamicin (27%) and third generation cephalosporins at 35% in a study conducted at the Aga Khan Hospital (Talbert et al. 2010). At Moi Teaching and Referral Hospital, the authors (Njuguna, Kiptoon, and Nyandiko 2014) of a study reviewing the causes for neonatal mortality among low-birth weight newborns recommended blood culture testing among neonates with suspected neonatal sepsis to identify the bacterial causes and their antibiotic sensitivities at the facility's newborn unit.

### 2.3 Risk Factors for Neonatal Sepsis

Neonatal sepsis is associated with a myriad of maternal and neonatal risk factors. In a study conducted in Oman, the maternal risk factors identified were chorioamnionitis, prolonged rupture of membranes, lack of intrapartum steroids use and intrapartum antibiotic use. Only the history of maternal steroid use was associated (p-value = 0.020) with having a gram-negative infection for neonatal sepsis (Abdellatif et al. 2019) . In Uganda, primiparity, intrapartum pyrexia (p=0.06) were not significantly associated with the occurrence of neonatal sepsis whereas prolonged rupture of membranes, lack of antenatal clinic attendance (p=0.02) and prolonged duration of labour (Mugalu, Nakakeeto, Kiguli, and Kaddu–Mulindwa 2006) were significantly associated. A seven times likelihood, AOR = 7.43 (95% CI: 2.04 – 27.1) was reported in Ethiopia among mothers with prolonged rupture of membranes and having a newborn with sepsis (Gebremedhin, Berhe, and Gebrekirstos 2016). In Taiwan (Kung et al. 2016), a statistically significant association between maternal steroid use and

neonatal sepsis ( $p=0.009$ ) was reported. However, there was no statistically significant association between prolonged rupture of membranes ( $p=0.840$ ) and neonatal sepsis (Kung et al. 2016).

Neonatal risk factors identified from previous studies included: sex, age, birth weight, gestational age, mode of delivery and place of delivery. In Nepal (Yadav et al. 2018), the authors reported that gender was not associated with neonatal sepsis ( $p >0.05$ ), however, neonates older than three days ( $p<0.05$ ), low birth weight ( $p<0.05$ ) and gestational age of 37 weeks or more ( $p<0.05$ ) were statistically associated with neonatal sepsis. In Uganda (Mugalu, Nakakeeto, Kiguli, and Kaddu–Mulindwa 2006), female neonates ( $p=0.01$ ) and neonatal age below seven days ( $p=0.01$ ) were statistically associated with neonatal sepsis. A study conducted in Ethiopia (Gebremedhin, Berhe, and Gebrekirstos 2016) reported that male neonates were 1.5 times (AOR =1.5; 95% CI: 0.6 ,3.60) more likely to contract neonatal sepsis compared to their female counterparts, however, this relationship was not statistically significant. Neonates with a birth weight of at least 2,500 grams were less likely to be diagnosed with neonatal sepsis compared to those with a birthweight below 2,500 grams. Similar findings were also reported among neonates born through caesarean section (Gebremedhin, Berhe, and Gebrekirstos 2016). In Taiwan (Kung et al. 2016), there was no statistically significant association between birth weight ( $p=0.052$ ), gestational age ( $p=0.333$ ) and being born outside a hospital ( $p=0.119$ ) and neonatal sepsis.

*Candida spp.* has been reported to cause high proportion of bloodstream infections among preterm neonates (Spiliopoulou et al. 2012). They often complicate the clinical course of preterm neonates with underlying disease; with common central nervous

system involvement and neurologic impairment (Legeay et al. 2015). The risk of neonatal candidemia has been reported to be increased by central mechanical ventilation and extended antimicrobial use (Legeay et al. 2015; Kung et al. 2016).

In Europe and North America, Group-B streptococcus (GBS) was the leading cause of neonatal sepsis with an incidence of 0.5 to 3 cases per 1,000 live births (Tsolia et al. 2003). Administration of intrapartum antimicrobial prophylaxis (IPAP) among women colonized with GBS has been reported as an effective measure of reducing early onset neonatal sepsis (EONS) among neonates born from those mothers (Bennett, Raphael Dolin, and Blaser 2019). Previous studies have indicated that GBS is a less common cause of neonatal sepsis in other continents, where gram negative organisms are isolated more frequently. Maternal bacterial colonization rates have been shown to vary in various countries and socioeconomic and ethnic groups in the same country. This could correlate with invasive infectious rates in neonates. In Athens-Greece, maternal colonization rate was higher among middle class pregnant women (Tsolia et al. 2003). The estimated GBS colonization rates in the USA and Canada range between 15-40% and 7-28% in European countries (Polin et al. 2012; Shane and Stoll 2014; Vergnano et al. 2011). Furthermore, studies in Greece reported 29% vertical transmission of GBS in which 22.5% of these mothers did not receive intrapartum antibiotic prophylaxis (Gkentzi et al. 2019). Maternal colonization rates have thus been associated with increased GBS infection rates among newborns (Gkentzi et al. 2019; Tsolia et al. 2003).

## **CHAPTER THREE**

### **3.0 METHODOLOGY**

#### **3.1 Study design**

This study adopted a cross sectional study design among to determine the bacterial causes of neonatal sepsis and their antibiotic sensitivity patterns among neonates admitted in a newborn unit of a tertiary teaching hospital.

#### **3.2 Study site**

The study was conducted at the newborn unit of Moi Teaching and Referral Hospital (MTRH). The facility is located in the Uasin Gishu County headquarters town of Eldoret, Kenya. It is the second largest national teaching and referral health facility located in the western part of the country. It has a bed-capacity of over 1000 serving the surrounding areas and referrals from far flung areas of the western and central parts of Kenya and neighboring countries. The hospital provides various services ranging from primary to tertiary care. It serves a large population of over 24 million people in the urban and rural populations.

The hospital's newborn unit (NBU) is located at the Riley Mother and Baby Hospital (RMBH) wing which is an extension of the teaching hospital set-up in 2009. It has a bed (crib) capacity of 70 but is often admits up to 185% of its capacity. Because of this congestion, there is increased risk of infection transmission among the newborns. The management protocol for neonatal sepsis in this newborn unit involves diagnosis of the disease using blood culture laboratory assays and this is followed up with pharmacological management. Empirical therapy for the newborns with suspected neonatal sepsis, the first-line regimen involves a combination of penicillin-gentamicin and third generation cephalosporins as second line treatment. Other commonly used antimicrobials include carbapenems, aminoglycosides, macrolides and glycopeptides.

### 3.3 Target population

All neonates admitted into the newborn unit during the study period

### 3.4 Study population

This study enrolled neonates admitted to the Newborn Unit of MTRH who had been diagnosed with neonatal sepsis clinically.

#### 3.4.1 Inclusion criteria

- i. Neonates with confirmed sepsis through a positive blood culture result.

#### 3.4.2 Exclusion criteria:

Neonates whose parents did not consent to take part in the study.

### 3.5 Study period

The study was carried out between September 2017 and July 2018.

### 3.6 Sample Size

The sample size determination was computed by using Fischer's formula for finite populations. According to a study done in Port Harcourt Teaching Hospital in Nigeria, 33.1% of the study participants had neonatal septicemia (West and Tabansi 2014). An average of 20 blood culture tests were being done at MTRH NBU monthly with an isolation rate was about 30 to 40 percent. This could translate to approximately 240 samples within 12 months period. To estimate our sample size, we used the finite population correction formula (Daniel, 1999) as follows:

$$n = \frac{NZ_{\alpha/2}^2 \times p \times (1 - p)}{d^2(N - 1) + Z_{\alpha/2}^2(p(1 - p))}$$

Where:

$n$  = The anticipated sample size with finite population correction

$N$  = The population size

$Z_{\alpha/2} = 1.96$ , standard normal variate

$p$  = Estimated prevalence of positive cultures in the population

$d$  = Margin of error at 5%

Calculating sample size yields the following figure.

$$n = \frac{(240 \times 1.96^2) \times (0.331 \times 0.669)}{(0.05^2 \times 239) + (1.96^2 \times 0.331 \times 0.669)}$$

$$n = \frac{204.1632}{1.4482} = 141 \text{ participants.}$$

### **3.7 Study Procedure and Data Collection Techniques**

#### **3.7.1 Sampling Technique**

Neonates who were suspected to have sepsis were screened for eligibility and sampled consecutively until the desired sample size was achieved.

#### **3.7.2 Study Procedure**

Neonates suspected to have sepsis had blood culture and sensitivity samples collected as part of routine care. The samples were processed as per good clinical laboratory standards of Moi Teaching and Referral Hospital whose microbiology laboratory has been accredited by the Kenya National Accreditation Services (KENAS). Blood cultures were taken after cleansing the skin site with 70% isopropyl alcohol for 30 seconds followed by 1-2% tincture iodine and isopropyl alcohol again. 1 mL blood sample were drawn from a peripheral vein and inoculated into BactT/Alert (Paed Plus) bottle. These were then put into a BACTEC incubator and observed for 5 days before reporting as negative. Identification of bacteria and antibiotic sensitivity testing were done by standard bacterial methods as per the manufacturing guidelines.

Parents of neonates with positive blood culture test results were approached by a trained research assistant or researcher for discussions on the study objective, procedures, risks and benefits. Those who were willing to have their newborns



participate in the study were consented using a written informed consent form. Maternal characteristics (parity, intrapartum pyrexia, urinary tract infections in pregnancy, level of education and age) information were collected using a structured interviewer administered questionnaire. Neonatal characteristics (gender, maturity, mode of delivery, place of delivery, birth weight and APGAR score) and clinical data were obtained from the medical records through chart review by the researcher and the information keyed into a data collection tool. Blood culture and sensitivity results were obtained from the laboratory reports in the participants' in-patient files.

### **3.8 Data Analysis and Presentation**

The bacterial isolates were classified as either gram-positive or gram-negative. The sensitivity of the various antimicrobials was assessed for the various isolates. The results were presented using tables. Data analysis was done using the statistical package for social sciences (SPSS) version 24.

Descriptive statistics were used to summarize the data. The median and the corresponding inter-quartile range were used to summarize continuous variables such as age, weight, APGAR score and time of onset of the symptoms among others. Categorical variables such as the gender, place of birth, mode of delivery and type of isolate were summarized using frequencies and percentages. Inferential statistics techniques using test of association and risk estimates were used to assess the relationships between the dependent and independent variables.

### **3.9 Ethical considerations**

Permission to undertake the study was sought from the Institutional Research and Ethics Committee (IREC) Moi University and the MTRH administration. An informed signed consent was obtained from the mothers of the neonates. There was no coercion or enticement for the parents to have their babies to participate in the study. All participants were accorded standard consideration and treatment as the rest of the neonates.

The mothers were informed of the study objectives, procedures, risks and benefits. Participants' information was processed and stored safely by the principal investigator and confidentiality was ensured. The study findings and recommendations will be shared with appropriate stakeholders through research conferences and scientific publications.

## CHAPTER FOUR

### RESULTS

#### 4.0 Description of Study Participants

In this study, 141 neonates were enrolled majority 81 (57.4%) of whom were female. The median gestational age was 37 weeks with the youngest being 22 weeks while the oldest neonate was 45 weeks. Spontaneous vaginal delivery (SVD) was the commonest mode of delivery for 110 (78%) of the neonates. The median birth weight was 2400 grams (IQR: 800 - 4700) with 66 (47.5%) having a normal birth weight.

**Table 1: Neonatal Characteristics**

<b>Neonatal characteristic</b>	<b>N</b>	<b>Frequency (%) / Median (IQR)</b>
<b>Gender</b>	141	
Male		60 (42.6%)
Female		81 (57.4%)
<b>Gestational Age</b>	125	37 (22 - 45) weeks
<b>Mode of Delivery</b>	141	
Spontaneous vaginal delivery		110 (78%)
Caeserian section		31 (22%)
<b>Birth Weight in grams</b>	139	2400g (800 - 4700)
ELBW ( $\leq$ 999g)		6 (4.3%)
VLBW (1000-1499g)		24 (17.3%)
LBW (1500-2499g)		41 (29.5%)
Normal (2500-3999g)		66 (47.5%)
Macrosomia ( $\geq$ 4000g)		2 (1.4%)
<b>Maturity</b>	141	
Preterm		98 (69.5%)
Term		43 (30.5%)

The median age of the mothers enrolled was 24 (IQR: 15 - 40) years majority (54.1%; n=72) of whom were primiparous. Nearly all (93.1%; n=108) respondents attended antenatal clinic, more than half (56.6%; n=69) were unemployed with the more than one-quarter having attended a tertiary educational institution (Table 2).

**Table 2: Characteristics of the participants' mothers**

<b>Maternal characteristic</b>	<b>N</b>	<b>Frequency (%) / Median (IQR)</b>
<b>Age</b>	136	24 (15 - 40) years
<b>Parity</b>	133	
Primiparous		72 (54.1%)
Multiparous		61 (45.9%)
2		29 (21.8%)
3		20 (15%)
4		2 (1.5%)
5		4 (3%)
6		3 (2.3%)
7		3 (2.3%)
<b>ANC Attendance</b>	116	
Yes		108 (93.1%)
No		8 (6.9%)
<b>UTI during pregnancy</b>	130	
Yes		19 (14.6%)
No		111 (85.4%)
<b>Employment Status</b>	122	
Employed		53 (43.4%)
Unemployed		69 (56.6%)
<b>Level of Education</b>	132	
Primary		50 (37.9%)
Secondary		45 (34.1%)
Tertiary		37 (28%)

#### 4.1 Causative organisms of bacterial neonatal sepsis at Moi Teaching and Referral Hospital's newborn unit.

This study enrolled 141 neonates of whom some had multiple isolates reported during blood culture testing. This led to a total of 151 bacterial isolates identified. Majority (46.4%; n=70) of these identified isolates were *Klebsiella spp* followed by *Coagulate negative staphylococcus* (27.8%; n=42). There were low frequencies of *Acinetobacter baumannii* (6.6%; n=10), *Staphylococcus aureus* (4.7%; n=7), *Enterococcus fecalis* (3.3%; n=5) and *Escherichia coli* (2.6%; n=4) reported (Table 3).

**Table 3: Frequency of Bacterial Isolates at MTRH newborn Unit**

<b>Bacterial isolate</b>	<b>Frequency</b>	<b>Percent (%)</b>
<i>Acinetobacter spp.</i>	10	6.6
<i>Alcaligenes spp.</i>	1	0.7
<i>Coagulate negative staphylococcus</i>	42	27.8
<i>Enterobactor spp</i>	4	2.6
<i>Enterococcus fecalis</i>	5	3.3
<i>Escherichia coli</i>	4	2.6
<i>Klebsiella spp.</i>	70	46.4
<i>Methicillin resistant staphylococcus aureus</i>	1	0.7
<i>Methicillin susceptible staphylococcus aureus</i>	3	2
<i>Micrococcus spp.</i>	1	0.7
<i>Pseudomonas auroginosa</i>	1	0.7
<i>Pseudomonas spp.</i>	1	0.7
<i>Staphylococcus aureus</i>	7	4.7
<i>Streptococcus virdans</i>	1	0.7
	<b>151</b>	<b>100</b>

#### 4.2 Antibiotic sensitivity patterns of organisms causing neonatal sepsis at Moi Teaching and Referral Hospital newborn unit.

The sensitivity testing was done for all the isolates identified. However, since *Klebsiella spp.* (a gram-negative bacteria) and *Coagulase Negative Staphylococcus* (CoNS) were the majority and formed the bulk of the burden of neonatal septicaemia in the newborn unit, this study focuses more on these two isolates. *Klebsiella spp.* was significantly more sensitive to meropenem (OR=3.298; 95% CI: 2.219-4.902). However, its sensitivity to amikacin (OR=1.116; 0.920-1.354) and cefepime (OR=1.157; 0.167-8.002) was not found to be statistically significant. Furthermore, there was a significantly higher likelihood of *Klebsiella spp.* being sensitive to Vancomycin (OR=2.455; 1.888-3.192,  $p < 0.001$ ) compared to other commonly used antibiotics as shown in Table 4.

**Table 4: *Klebsiella spp.* Antibiotic Sensitivity and Resistance Patterns (N=70)**

Antibiotic	Pearson chi-square test					p-value
	n(%)	Pattern	Odds Ratio	95% Confidence Interval of the Difference		
				Lower	Upper	
Vancomycin	70 (100)	Resistant	2.455	1.888	3.192	<0.001
Meropenem	57 (81.4)	Sensitive	3.298	2.219	4.902	<0.001
Ceftriaxone	66 (94.3)	Resistant	1.076	0.990	1.061	0.161
Amikacin	54 (77.1)	Sensitive	1.116	0.920	1.354	0.270
Cefepime	68 (97.1)	Sensitive	1.157	0.167	8.002	0.882
Gentamycin	66 (94.3)	Resistant	1.076	0.990	1.061	0.161
Cefotaxime	67 (95.7)	Resistant	1.077	0.983	1.180	0.122

*Coagulase negative staphylococcus* (CoNS) – a gram-positive bacteria - was significantly sensitive to vancomycin (p-value <0.001; OR=5.710; 3.478-9.374). It also had higher odds for being sensitive to amikacin (OR=1.497; 0.884-2.535) however, this relationship was not found to be statistically significant. Furthermore, this study reports that CoNS was resistant to the remaining antibiotics tested, with the resistance statistically significant for meropenem as shown on Table 5.

**Table 5: *Coagulase Negative Staphylococcus* (CoNS) antibiotic sensitivity pattern (N=42)**

Antibiotic	Pearson chi-square test					
	n(%)	Pattern	Odds Ratio	95% Confidence Interval		p-value
				Lower	Upper	
Cefepime	42 (100)	Resistant	1.038	1.001	1.077	0.208
Cefotaxime	41 (97.6)	Resistant	1.086	1.004	1.175	0.116
Vancomycin	33 (78.6)	Sensitive	5.710	3.478	9.374	<0.001
Penicillin	31 (73.8)	Resistant	0.985	0.937	1.036	0.481
Meropenem	38 (90.5)	Resistant	2.739	2.061	3.642	<0.001
Amikacin	27 (64.3)	Sensitive	1.497	0.884	2.535	0.142
Gentamycin	36 (85.7)	Resistant	1.005	0.868	1.162	0.951
Ceftriaxone	40 (95.2)	Resistant	1.070	0.974	1.176	0.238

### 4.3 Risk factors for neonatal sepsis at Moi Teaching and referral Hospital

#### Newborn unit

Neonatal risk factors such as spontaneous vaginal delivery, hospital delivery, prematurity, low birth weight and 5-minute APGAR score after birth of less than 6 were not found to be associated with the occurrence of neonatal sepsis (Table 6).

**Table 6: Neonatal Risk factors associated with Neonatal Sepsis at MTRH newborn unit.**

Neonatal Characteristics	<i>Klebsiella sp.</i>	CoNS
<b>Mode of Delivery (N=141)</b> SVD = 110 (78%) CS = 31 (22%)	p-value = 0.256 RR = 0.868 (0.698 – 1.080)	p-value = 0.557 RR = 1.278 (0.531 – 3.076)
<b>Birthplace (n=134)</b> Hospital = 125 (93.3%) Home = 9 (6.7%)	p-value = 0.144 RR = 1.476 (0.733 – 2.975)	p-value = 0.207 RR = 0.508 (0.194 – 1.332)
<b>Maturity (N=141)</b> Term = 98 (69.5%) Preterm = 43 (30.5%)	p-value = 0.106 RR = 0.826 (0.652 – 1.045)	p-value = 0.792 RR = 1.094 (0.561 – 2.135)
<b>Apgar Score at 5 minutes (N=105)</b> ≤6 = 37 (35.2%) >6 = 68 (64.8%)	p-value = 0.259 RR = 1.532 (0.733 – 3.202)	p-value = 0.352 RR = 0.082 (0.669 – 1.163)



There were no statistically significant relationships demonstrated between maternal factors and occurrence of neonatal sepsis. These factors including primiparity, intrapartum pyrexia, maternal age, level of education, urinary tract infection during pregnancy, prolonged rupture of membranes and mode of delivery with the corresponding p-values and risk ratios are indicated as shown on table 7.

**Table 7: Maternal Risk Factors Associated with Neonatal Sepsis**

<b>Maternal Characteristics</b>	<b><i>Klebsiella sp.</i></b>	<b>CoNS</b>
<b>Parity</b> (Primi/ Multigravida)	p-value = 0.322 RR – 1.116 (0.895 – 1.391)	p-value = 0.484 RR – 0.787 (0.401 – 1.543)
<b>Intrapartum Pyrexia</b>	p-value = 0.814	p-value = 0.331
<b>Maternal Age</b>	p-value = 0.630	p-value = 0.404
<b>Level of Education</b>	p-value = 0.365	p-value = 0.191
<b>UTI in pregnancy</b>	p-value = 0.304	p-value = 0.164

## CHAPTER FIVE

### DISCUSSION

#### 5.0 Introduction

This study purposed to determine the causative organisms, antibiotic sensitivity patterns and risk factors associated with neonatal sepsis at the newborn unit of Moi Teaching and Referral Hospital. This section compares the current study's findings with those from other setups to determine reasons for concurrence or contrast.

#### 5.1 Causative organisms of bacterial neonatal sepsis at Moi Teaching and Referral Hospital's newborn unit.

Neonatal sepsis could be caused by various pathogenic bacteria that could be classified as either gram-positive or gram-negative based on their gram staining patterns. In this study, the leading causative organism of neonatal sepsis among all the enrolled children was *Klebsiella spp* (a gram-negative bacteria) accounting for nearly half of all the bacterial isolates. The second most common bacteria isolated among the neonates enrolled in the study was *Coagulase negative Staphylococcus aureus* (CoNS) a gram-positive bacterium that accounted for more than one-quarter of all the bacteria isolated. Although there were other bacteria isolated from the neonates enrolled, their proportions were negligible with *Acinetobacter baumannii* (a gram-negative bacteria) being the third most prevalent bacteria isolated.

These results are consistent with previous studies conducted in Kenya (Talbert et al. 2010) and India (Verma et al. 2015). In the Kenyan study conducted at Kilifi District Hospital, *Klebsiella spp* was the most prevalent of all the bacterial isolates obtained from the enrolled neonates and the leading gram negative bacteria seen (Talbert et al. 2010). This similarity could be attributed to the fact that both studies were conducted in public hospitals in the same country where infection control strategies and study

population are similar. In the Indian study, it was reported that *Klebsiella spp* was the most common (48.1%) bacteria seen at the neonatal intensive care unit (NICU) of S.P. Medical College tertiary hospital in Bikaner – Rajasthan (Verma et al. 2015). This similarity could be attributed to similarity in study settings, in that; both MTRH and S.P. Medical College are tertiary hospitals in developing economies where neonates presenting with infection are often referred to.

However, the results from this study contrasted with those from Kenya (Kohli-Kochhar, Omuse, and Revathi 2011), Bangladesh (Mannan et al. 2018) and Arab States in the Gulf region – Kuwait, Saudi Arabia and the United Arab Emirates - (Hammoud et al. 2017). In the Kenyan ten year (2000 - 2009) retrospective review conducted in Aga Khan university hospital – a private teaching hospital -, CoNS was the most prevalent (27%) of the bacteria isolated from the neonates followed by *Klebsiella spp* (Kohli-Kochhar, Omuse, and Revathi 2011). This difference in study findings could be attributed to the difference in study settings and design. The current study was conducted at a public teaching hospital which receives neonates from all socioeconomic backgrounds while the Aga Khan study was conducted in a private teaching hospital which likely receives children from affluent background. While the current study adopted a cross-sectional descriptive study design, the Aga Khan study was a retrospective and over a long period which is may be fraught with incomplete data. This could explain the inconsistencies in study findings.

In the Bangladesh study conducted at Ad-din Medical College Hospital (AMCH) in Dhaka; it was reported that CoNS (68.4%) was the most prevalent followed by *Acinetobacter baumannii* at 18.4% (Mannan et al. 2018). There was no *Klebsiella spp* reported. This difference could be attributed to differences in study designs as the

Bangladesh study was prospective over a period of nine-months while the current study was cross-sectional. The Bangladesh study further employed other investigatory techniques such as C-Reactive Proteins (CRP), complete blood count (CBC) and blood slide for malarial parasites which were not investigated in the current study.

In the Gulf Region states (Hammoud et al. 2017), it was reported that CoNS was the most prevalent (34.65%) followed by *Klebsiella spp* (22.8%), *E. coli* (4.845) and *Acinetobacter spp* (4.59%). This prospective study conducted in the five NICUs of Kuwait, United Arab Emirates (UAE) and Saudi Arabia was different from the current study due to its study design, target population (late onset sepsis) and sample size (n=780). This could explain the difference in the study findings.

## **5.2 Antibiotic sensitivity of organisms causing neonatal sepsis at Moi Teaching and Referral Hospital newborn unit**

*Klebsiella spp.* was sensitive to meropenem (OR=3.298; 95% CI: 2.219-4.902, p<0.001) and amikacin (OR=1.116; 0.920-1.354, p=0.270). However, there were significantly higher odds of *klebsiella* resistance to vancomycin (OR=2.455; 1.888-3.192, p<0.001) compared to gentamicin (OR=1.076 0.990-1.061, p=0.161). The sensitivity data in this study were similar to those found in India (Verma et al. 2015) where *Klebsiella* was found to be sensitive to amikacin and resistant to penicillin. Gentamicin sensitivity results are also similar to a study in the Gulf Region States where there was a 7.09 % increased chance of resistance the gram-negative bacteria to gentamicin (Hammoud et al. 2017). The findings of the current study contrast those from another Kenyan study conducted at the Aga Khan University Hospital, which found *Klebsiella* to be 72.4% sensitive to gentamicin and amikacin at 94.1% (Kohli-Kochhar, Omuse, and Revathi 2011).

*Coagulase negative Staphylococcus aureus* (CoNS) was sensitive to vancomycin (OR=5.710; 3.478-9.374) and amikacin (OR=1.497; 0.884-2.535), but resistant to the rest of the antimicrobials. These findings are similar to an Indian study which found CoNS to be resistant to gentamicin, ceftriaxone and ceftazidime but sensitive to vancomycin. The current study's findings further match those from Bangladesh (Mannan et al. 2018) where CoNS was reported to be sensitive to vancomycin (74%) but resistant to meropenem (22%). In a previous Kenyan study (Kohli-Kochhar, Omuse, and Revathi 2011), it was reported that CoNS was sensitive to gentamicin (83.4%) which contrasts the findings of the current study. This variation could be attributed to indiscriminate use of gentamicin as empirical first-line antimicrobial over the years without laboratory guidance.

### **5.3 Risk factors for neonatal sepsis at Moi Teaching and referral Hospital**

#### **Newborn unit**

##### **5.3.1 Maternal Risk Factors and Occurrence of Neonatal Sepsis**

In this study, there was no statistically significant relationships demonstrated between maternal factors and occurrence of neonatal sepsis. These factors include primiparity, intrapartum pyrexia, maternal age, level of education, urinary tract infection during pregnancy, prolonged rupture of membranes and mode of delivery. These findings are similar to studies conducted in Saudi Arabia (Al-Zahrani et al. 2015), Uganda (Mugalu, Nakakeeto, Kiguli, and Kaddu -Mulindwa 2006) and South Korea (Kung et al. 2016). In a study conducted at King Abdul Aziz Specialist Hospital in Taif, Saudi Arabia (Al-Zahrani et al. 2015), it was reported that there was no statistically significant association between intrapartum pyrexia ( $p=0.110$ ) or prolonged rupture of membrane ( $0.210$ ) and the occurrence of neonatal sepsis. Although this study also adopted a cross-sectional study design, Al-Zahrani and colleagues however stratified

their participants into three groups (proven early-onset neonatal sepsis, clinical early-onset neonatal sepsis and negative infectious status) while the current study only had a single group of neonates with sepsis.

In Uganda's Mulago hospital study (Mugalu, Nakakeeto, Kiguli, and Kaddu - Mulindwa 2006) assessing the aetiology and risk factors for neonatal sepsis, it was determined that primiparity (0.23), intrapartum pyrexia (0.060), prolonged rupture of membranes (0.140) and mode of delivery (0.070) was not significantly associated with the occurrence of neonatal sepsis. These findings were also similar to a study in South Korea (Kung et al. 2016) which found no statistically significant association between prolonged rupture of membranes (0.840) and occurrence of neonatal sepsis.

The findings of this study, however, contrast those found in Ethiopia's public hospitals of Mekelle City in Tigray region (Gebremedhin, Berhe, and Gebrekirstos 2016). This study in Ethiopia found that occurrence of neonatal sepsis was more likely in infants of mothers who had had intrapartum pyrexia (AOR = 6.08), urinary tract infection during pregnancy (AOR = 5.23) and prolonged rupture of membranes (AOR = 7.4).

### **5.3.2 Neonatal Risk Factors and Occurrence of Neonatal Sepsis**

Neonatal risk factors such as spontaneous vaginal delivery, hospital delivery, prematurity, low birth weight and 5-minute APGAR score of  $\leq 6$  were, in this study, found not to be associated with the presence of neonatal sepsis in the infants studied. These results matched the findings in Saudi Arabia (Al-Zahrani et al. 2015), Uganda (Mugalu, Nakakeeto, Kiguli, and Kaddu - Mulindwa 2006) and South Korea (Kung et al. 2016). Hospital birth was not associated with occurrence of neonatal sepsis in Uganda ( $p$ -value = 0.07) and Korea (0.119) (Mugalu, Nakakeeto, Kiguli, and Kaddu -

Mulindwa 2006; Kung et al. 2016). There was no statistically significant association between prematurity and occurrence of neonatal sepsis reported in South Korea (0.333) (Kung et al. 2016), however, a statistically significant relationship was reported in Saudi Arabia (0.007) (Al-Zahrani et al. 2015). Low birthweight was not significantly associated with neonatal sepsis in Saudi Arabia (0.880) (Al-Zahrani et al. 2015) and South Korea (0.052) (Kung et al. 2016). Five-minute APGAR score of  $\leq 6$  was not associated with the occurrence of neonatal sepsis in South Korea (0.052), however, high odds were reported in Ethiopia (AOR = 68.9) (Gebremedhin, Berhe, and Gebrekirstos 2016).

## CHAPTER SIX

### 6.0 CONCLUSIONS, RECOMMENDATIONS AND STUDY LIMITATIONS

#### 6.1 Conclusions:

- i. The main causative organism of neonatal sepsis was *Klebsiella pneumoniae*.
- ii. Both *Klebsiella pneumoniae* and *Coagulate negative staphylococcus aureus* were sensitive to meropenem and amikacin antibiotics.
- iii. Neonatal (place of birth, mode of delivery, maturity and 5-min APGAR score) and maternal risk factors (age, parity, intrapartum pyrexia and urinary tract infection during pregnancy) were not seen to be significantly associated with increased likelihood for neonatal sepsis occurrence.

#### 6.2 Study Recommendations:

- i. Infection control measures targeting *Klebsiella pneumoniae* and *Coagulate negative staphylococcus aureus* should be instituted to reduce the prevalence of the organism.
- ii. Current first line antibiotic regimen of penicillin and gentamycin should be reviewed.
- iii. Future larger studies designed to identify other risk factors for neonatal sepsis should be conducted.

#### 6.3 Study Limitations

The study was not able to assess the environmental risk factors associated with neonatal sepsis due the study design and incomplete data.



## REFERENCES

- Abdellatif, Mohamed, Murtadha Al-Khabori, Assad Ur Rahman, Ashfaq Ahmad Khan, Ahmed Al-Farsi, and Khalid Ali. 2019. "Outcome of Late-Onset Neonatal Sepsis at a Tertiary Hospital in Oman." *Oman Medical Journal* 34 (4): 302–7.
- Al-Zahrani, Ali Kh, Mabrouk M. Ghonaim, Yousri M. Hussein, Emad M. Eed, Amany S. Khalifa, and Lalia S. Dorgham. 2015. "Evaluation of Recent Methods versus Conventional Methods for Diagnosis of Early-Onset Neonatal Sepsis." *Journal of Infection in Developing Countries* 9 (4): 388–93.
- Apondi, Ogalo Edith, Owuor Chrispine Oduor, Boor Kipyego Gye, and Mutai Kennedy Kipkoech. 2016. "High Prevalence of Multi-Drug Resistant Klebsiella Pneumoniae in a Tertiary Teaching Hospital in Western Kenya." *African Journal of Infectious Diseases* 10 (2): 89–95.
- Bennett, John E., Raphael Dolin, and Martin J. Blaser. 2019. "Mandell, Douglas, and Bennett's Principles and Practice of Infectious ... -." 2019. [https://books.google.co.ke/books?id=BseNCgAAQBAJ&printsec=frontcover&dq=Mandell,+Douglas,+and+Bennett%27s+principles+and+practice+of+infectious+diseases.&hl=en&sa=X&ved=0ahUKEwiRILvs1eDnAhUOT8AKHSHKHCzAQ6AEIMzAC#v=onepage&q=Mandell%2C Douglas%2C and Bennet](https://books.google.co.ke/books?id=BseNCgAAQBAJ&printsec=frontcover&dq=Mandell,+Douglas,+and+Bennett%27s+principles+and+practice+of+infectious+diseases.&hl=en&sa=X&ved=0ahUKEwiRILvs1eDnAhUOT8AKHSHKHCzAQ6AEIMzAC#v=onepage&q=Mandell%2C%20Douglas%2C%20and%20Bennet).
- Blomberg, Bjørn, Roland Jureen, Karim P Manji, Bushir S Tamim, Davis S M Mwakagile, Willy K Urassa, Maulidi Fataki, Viola Msangi, Marit G Tellevik, and Samwel Y Maselle. 2005. "High Rate of Fatal Cases of Pediatric Septicemia Caused by Gram-Negative Bacteria with Extended-Spectrum Beta-Lactamases in Dar Es Salaam, Tanzania." *Journal of Clinical Microbiology* 43 (2): 745–49.
- Cailes, Benjamin, Christina Kortsalioudaki, Jim Buttery, Santosh Pattanayak, Anne Greenough, Jean Matthes, Alison Bedford Russell, Nigel Kennea, and Paul T. Heath. 2018. "Epidemiology of UK Neonatal Infections: The NeonIN Infection Surveillance Network." *Archives of Disease in Childhood: Fetal and Neonatal Edition* 103 (6).
- Chacko, Betty, and Inderpreet Sohi. n.d. "Early Onset Neonatal Sepsis."
- Darmstadt, Gary L, Maneesh Batra, and Anita K M Zaidi. 2009. "Oral Antibiotics in the Management of Serious Neonatal Bacterial Infections in Developing Country Communities." *The Pediatric Infectious Disease Journal* 28 (1): S31–36.
- Dong, Huaifu, Huiping Cao, and Haiyan Zheng. 2017. "Pathogenic Bacteria Distributions and Drug Resistance Analysis in 96 Cases of Neonatal Sepsis." *BMC Pediatrics* 17 (1): 44.
- Dong, Ying, Kirsten Glaser, and Christian P. Speer. 2019. "Late-Onset Sepsis Caused by Gram-Negative Bacteria in Very Low Birth Weight Infants: A Systematic Review." *Expert Review of Anti-Infective Therapy*. Taylor and Francis Ltd.
- Dong, Y., & Speer, C. P. (2015). Late-onset neonatal sepsis: recent developments. *Archives of Disease in Childhood-Fetal and Neonatal Edition*, 100(3), F257-F263.
- Dong, Y., Speer, C. P., & Glaser, K. (2018). Beyond sepsis: Staphylococcus epidermidis is an underestimated but significant contributor to neonatal morbidity. *Virulence*, 9(1), 621-633.

- Downie, Lilian, Raffaella Armiento, Rami Subhi, Julian Kelly, Vanessa Clifford, and Trevor Duke. 2013. "Community-Acquired Neonatal and Infant Sepsis in Developing Countries: Efficacy of WHO's Currently Recommended Antibiotics - Systematic Review and Meta-Analysis." *Archives of Disease in Childhood* 98 (2): 146–54.
- Fleischmann-Struzek, Carolin, David M. Goldfarb, Peter Schlattmann, Luregn J. Schlapbach, Konrad Reinhart, and Niranjana Kissoon. 2018. "The Global Burden of Paediatric and Neonatal Sepsis: A Systematic Review." *The Lancet Respiratory Medicine* 6 (3): 223–30.
- Gebremedhin, Destaalem, Haftu Berhe, and Kahsu Gebrekirstos. 2016. "Risk Factors for Neonatal Sepsis in Public Hospitals of Mekelle City, North Ethiopia, 2015: Unmatched Case Control Study." *PLoS ONE* 11 (5): 1–10.
- Gkentzi, Despoina, Christina Kortsalioudaki, Benjamin Campbell Cailles, Theoklis Zaoutis, John Kopsidas, Maria Tsolia, Nikos Spyridis, et al. 2019. "Epidemiology of Infections and Antimicrobial Use in Greek Neonatal Units." *Archives of Disease in Childhood: Fetal and Neonatal Edition* 104 (3).
- Gray, James W. 2007. "Surveillance of Infection in Neonatal Intensive Care Units." *Early Human Development* 83 (3): 157–63.
- Greenberg, Rachel G., Sarah Kandefor, Barbara T. Do, P. Brian Smith, Barbara J. Stoll, Edward F. Bell, Waldemar A. Carlo, et al. 2017. "Late-Onset Sepsis in Extremely Premature Infants: 2000-2011." *Pediatric Infectious Disease Journal*. Lippincott Williams and Wilkins.
- Hammoud, Majeda S., Abdullah Al-Taiar, Sameer Y. Al-Abdi, Hussain Bozaid, Anwar Khan, Laila M. AlMuhairi, and Moghis Ur Rehman. 2017a. "Late-Onset Neonatal Sepsis in Arab States in the Gulf Region: Two-Year Prospective Study." *International Journal of Infectious Diseases* 55: 125–30.
- 2017b. "Late-Onset Neonatal Sepsis in Arab States in the Gulf Region: Two-Year Prospective Study." *International Journal of Infectious Diseases* 55 (February): 125–30.
- Huynh, B. T., Padget, M., Garin, B., Herindrainy, P., Kermorvant-Duchemin, E., Watier, L., ... & Delarocque-Astagneau, E. (2015). Burden of bacterial resistance among neonatal infections in low income countries: how convincing is the epidemiological evidence?. *BMC infectious diseases*, 15(1), 1-13.
- Irshad, Mohammad, and Moshin Hayat. 2019. "Neonatal Sepsis." *The Professional Medical Journal* 26 (4): 608–14.
- Kang, Cheol-In, Jae-Hoon Song, Doo Ryeon Chung, Kyong Ran Peck, Kwan Soo Ko, Joon-Sup Yeom, Hyun Kyun Ki, et al. 2011. "Risk Factors and Pathogenic Significance of Severe Sepsis and Septic Shock in 2286 Patients with Gram-Negative Bacteremia Chisook Moon m , on Behalf of Korean Network for Study of Infectious Diseases (KONSID)." *Journal of Infection* 62: 26–33.
- Kiwanuka, Julius, Joel Bazira, Juliet Mwangi, Dickson Tumusiime, Eunice Nyesigire, Nkangi Lwanga, Benjamin C Warf, Vivek Kapur, Mary Poss, and Steven J Schiff. 2013. "The Microbial Spectrum of Neonatal Sepsis in Uganda: Recovery of Culturable Bacteria in Mother-Infant Pairs." *PLoS One* 8 (8): e72775.

- Kohli-Kochhar, R., Omuse, G., & Revathi, G. (2011). A ten-year review of neonatal bloodstream infections in a tertiary private hospital in Kenya. *Journal of infection in developing countries*, 5(11), 799.
- Kung, Yin Hsiang, Yi Fan Hsieh, Yi Hao Weng, Rey In Lien, Jian Luo, Yuan Wang, Yhu Chering Huang, Chyi Liang Chen, and Chih Jung Chen. 2016. "Risk Factors of Late-Onset Neonatal Sepsis in Taiwan: A Matched Case-Control Study." *Journal of Microbiology, Immunology and Infection* 49 (3): 430–35.
- Legeay, C., Bourigault, C., Lepelletier, D., & Zahar, J. R. (2015). Prevention of healthcare-associated infections in neonates: room for improvement. *Journal of Hospital Infection*, 89(4), 319-323.
- Macharashvili, Nino, Ekaterina Kourbatova, Maia Butsashvili, Tengiz Tsertsvadze, Louise-Anne McNutt, and Michael K Leonard. 2009. "Etiology of Neonatal Blood Stream Infections in Tbilisi, Republic of Georgia." *International Journal of Infectious Diseases* 13 (4): 499–505.
- Mannan, Md Abdul, Shahed Iqbal, SM Rezaul Karim, Talim Uddin Ahmed, Md Hakimul Haque Khan, Ashraf Uddin Ahmed, Subir Dey, Sabina Yasmin, and Navila Ferdous. 2018. "Bacterial Isolates of Early Onset Neonatal Sepsis and Their Antibiotic Susceptibility Pattern." *Chattagram Maa-O-Shishu Hospital Medical College Journal* 17 (1): 3–8.
- Mhada, Tumaini V, Francis Fredrick, Mecky I Matee, and Augustine Massawe. 2012. "Neonatal Sepsis at Muhimbili National Hospital, Dar Es Salaam, Tanzania; Aetiology, Antimicrobial Sensitivity Pattern and Clinical Outcome." *BMC Public Health* 12 (1): 904.
- Mir, Fatima, Shiyam Sundar Tikmani, Sadia Shakoor, Haider Javed Warraich, Shazia Sultana, Syed Asad Ali, and Anita K M Zaidi. 2011. "Incidence and Etiology of Omphalitis in Pakistan: A Community-Based Cohort Study." *The Journal of Infection in Developing Countries* 5 (12): 828–33.
- Mugalu, J, M K Nakakeeto, S Kiguli, and Deo H Kaddu–Mulindwa. 2006. "Aetiology, Risk Factors and Immediate Outcome of Bacteriologically Confirmed Neonatal Septicaemia in Mulago Hospital, Uganda." *African Health Sciences* 6 (2): 120–26.
- Mugalu, J., Nakakeeto, M. K., Kiguli, S., & Kaddu–Mulindwa, D. H. (2006). Aetiology, risk factors and immediate outcome of bacteriologically confirmed neonatal septicaemia in Mulago hospital, Uganda. *African health sciences*, 6(2), 120-126.
- Muller-Pebody, B., Johnson, A. P., Heath, P. T., Gilbert, R. E., Henderson, K. L., Sharland, M., & iCAP Group (Improving Antibiotic Prescribing in Primary Care. (2011). Empirical treatment of neonatal sepsis: are the current guidelines adequate?. *Archives of Disease in Childhood-Fetal and Neonatal Edition*, 96(1), F4-F8.
- Muthwii, F, M Chege, M Muiva, and M Habtu. 2019. "Factors Associated with Severity of Neonatal Sepsis on Admission in Kenyatta Hospital Paediatric Wards, Kenya: A Descriptive Cross-Sectional Study | Muthwii | East African Medical Journal." *AJOL*. 2019.

- Njuguna, Festus M, Paul Kiptoon, and Winston Nyandiko. 2014. "An Assessment of the Overall Mortality of Low Birth Weight Neonates at the New Birth Units of the Moi Teaching and Referral Hospital in Eldoret, Kenya." *European Journal of Biology and Medical Science Research* 2 (3): 63–71.
- Obiero, Christina W, MB ChB, Anna C Seale, James A Berkley, and Luisa Galli Florence. 2015. "Empiric Treatment of Neonatal Sepsis in Developing Countries Europe PMC Funders Group." *Pediatric Infectious Disease Journal*. 34 (6): 659–61.
- Ojukwu, Juliana U, Leonard E Abonyi, Jude Ugwu, and Ikechukwu K Orji. 2006. "Neonatal Septicemia in High Risk Babies in South-Eastern Nigeria." *Journal of Perinatal Medicine* 34 (2): 166–72.
- Polin, Richard A., Lu Ann Papile, Jill E. Baley, William Benitz, Waldemar A. Carlo, James Cummings, Praveen Kumar, et al. 2012. "Management of Neonates with Suspected or Proven Early-Onset Bacterial Sepsis." *Pediatrics* 129 (5): 1006–15.
- Ramasethu, Jayashree, and Tetsuya Kawakita. 2017. "Antibiotic Stewardship in Perinatal and Neonatal Care." *Seminars in Fetal and Neonatal Medicine* 22 (5): 278–83.
- Saini, Shiv Sajan, Sourabh Dutta, Pallab Ray, and Anil Narang. 2011. "Short Course versus 7-Day Course of Intravenous Antibiotics for Probable Neonatal Septicemia: A Pilot, Open-Label, Randomized Controlled Trial." *Indian Pediatrics* 48 (1): 19–24.
- Seale, Anna C., Hannah Blencowe, Alexander A. Manu, Harish Nair, Rajiv Bahl, Shamim A. Qazi, Anita K. Zaidi, et al. 2014. "Estimates of Possible Severe Bacterial Infection in Neonates in Sub-Saharan Africa, South Asia, and Latin America for 2012: A Systematic Review and Meta-Analysis." *The Lancet Infectious Diseases* 14 (8): 731–41.
- Shane, Andi L., and Barbara J. Stoll. 2014. "Neonatal Sepsis: Progress towards Improved Outcomes." *Journal of Infection* 68 (SUPPL1).
- Shane, Andi L, Pablo J Sánchez, and Barbara J Stoll. 2017. "Seminar Neonatal Sepsis."
- Shobowale, Emmanuel, Adaobi Solarin, Charles Elikwu, Kenneth Onyedibe, Ibronke Akinola, and Abiodun Faniran. 2017. "Neonatal Sepsis in a Nigerian Private Tertiary Hospital: Bacterial Isolates, Risk Factors, and Antibiotic Susceptibility Patterns." *Annals of African Medicine* 16 (2): 52–58.
- Shrestha, Shree Krishna, Jagat Jeevan Ghimire, Ramchandra Bastola, and Rupa Gurung. 2018. "Clinical and Bacteriological Profile of Neonates Admitted in the Neonatal Care Unit of Western Regional Hospital." *Medical Journal of Pokhara Academy of Health Sciences* 1 (1): 4–7.
- Sigaúque, Betuel, Anna Roca, Inácio Mandomando, Luís Morais, Llorenç Quintó, Jahit Sacarlal, Eusébio Macete, Tacilta Nhamposa, Sónia Machevo, and Pedro Aide. 2009. "Community-Acquired Bacteremia among Children Admitted to a Rural Hospital in Mozambique." *The Pediatric Infectious Disease Journal* 28 (2): 108–13.

- Sivanandan, Sindhu, Amuchou S Soraisham, and Kamala Swarnam. 2011. "Choice and Duration of Antimicrobial Therapy for Neonatal Sepsis and Meningitis." *International Journal of Pediatrics* 2011: 1–9.
- Spiliopoulou, A., G. Dimitriou, E. Jelastopulu, I. Giannakopoulos, E. D. Anastassiou, and Myrto Christofidou. 2012. "Neonatal Intensive Care Unit Candidemia: Epidemiology, Risk Factors, Outcome, and Critical Review of Published Case Series." *Mycopathologia* 173 (4): 219–28.
- Stockmann, Chris, Michael G. Spigarelli, Sarah C. Campbell, Jonathan E. Constance, Joshua D. Courter, Emily A. Thorell, Jared Olson, and Catherine M.T. Sherwin. 2014. "Considerations in the Pharmacologic Treatment and Prevention of Neonatal Sepsis." *Pediatric Drugs* 16 (1): 67–81.
- Sundaram, Venkataseshan, Praveen Kumar, and Anil Narang. 2009. "Bacterial Profile of Early versus Late Onset Neonatal Sepsis in a North Indian Tertiary Care Centre: Heading towards a Change." *Journal of Pediatric Infectious Diseases* 4 (03): 241–45.
- Talbert, Alison W A, Michael Mwaniki, M B B Ch, Salim Mwarumba, Charles R J C Newton, and James A Berkley. 2010. "Invasive Bacterial Infections in Neonates and Young Infants Born Outside Hospital Admitted to a Rural Hospital in Kenya." *Pediatric Infectious Disease Journal* 29 (10): 945–49.
- Tsolia, M., M. Psoma, S. Gavrili, V. Petrochilou, S. Michalas, N. Legakis, and Th. Karpathios. 2003. "Group B Streptococcus Colonization of Greek Pregnant Women and Neonates: Prevalence, Risk Factors and Serotypes." *Clinical Microbiology and Infection* 9 (8): 832–38.
- Vergnano, S., Menson, E., Kennea, N., Embleton, N., Russell, A. B., Watts, T., ... & Heath, P. T. (2011). Neonatal infections in England: the NeonIN surveillance network. *Archives of Disease in Childhood-Fetal and Neonatal Edition*, 96(1), F9-F14.
- Verma, P., Berwal, P. K., Nagaraj, N., Swami, S., Jivaji, P., & Narayan, S. (2015). Neonatal sepsis: epidemiology, clinical spectrum, recent antimicrobial agents and their antibiotic susceptibility pattern. *International Journal of Contemporary Pediatrics* 2(3), 176-180.
- West, BA, and PN Tabansi. 2014. "Prevalence of Neonatal Septicaemia in the University of Port Harcourt Teaching Hospital, Nigeria." *Nigerian Journal of Paediatrics* 41 (1): 33.
- Yadav, Nikita Singh, Saroj Sharma, Dhiraj Kumar Chaudhary, Prabhat Panthi, Pankaj Pokhrel, Anil Shrestha, and Pappu Kumar Mandal. 2018. "Bacteriological Profile of Neonatal Sepsis and Antibiotic Susceptibility Pattern of Isolates Admitted at Kanti Children's Hospital, Kathmandu, Nepal." *BMC Research Notes* 11 (1): 1–6.
- Zaidi, A. K., Thaver, D., Ali, S. A., & Khan, T. A. (2009). Pathogens associated with sepsis in newborns and young infants in developing countries. *The Pediatric infectious disease journal*, 28(1), S10-S18.

## APPENDICES

### APPENDIX I: PARENTAL INFORMED CONSENT FORM

**Consent to participate in the study:** *Read this information carefully before you decide whether you want to take part in this study.*

The purpose of this study is to determine the cause(s) of infection and risk factors associated with bacterial infections at Moi Teaching and Referral Hospital newborn unit. It is intended purely for research purpose only though we believe that any useful information obtained can be used or shared by the hospital and other policy formulators to improve healthcare service to these newborns.

**Study Procedure:** This involves filling out a data collection form detailing the mother and baby's biodata, as well as the presenting symptoms and signs of your baby regarding this current illness. Other information will also be gathered laboratory investigation results for analysis. All these data shall be completely anonymous and confidential since we will employ only serial numbers instead of names.

**Risks:** This study has no risks associated with it. It will not interrupt the treatment your baby will be put on. The baby will receive treatment as scheduled or prescribed by ward doctors based on the hospital and Ministry neonatal protocols.

**Benefits:** There are no financial or direct medical benefits to you or your child for participating in this study. It is our hope that the study will be potentially beneficial in terms of improved healthcare service delivery based on the recommendations out of study results.

**Alternative Procedures:** Participation in this study is voluntary. You have the right to decide to take part or decline the study.

**Confidentiality:** All data collection tools used will be identified by numbers or codes to protect any information that could be used to identify your baby. Results of this study may be published, but no names or other identifying information will be released. This research will be conducted in accordance with the Kenyan laws and regulations that protect rights of human research process. All records and other information obtained will be kept strictly confidential and your baby's protected health information will not be used without permission

**Person to Contact:** If you have queries, complaints or concerns regarding this study, you can contact the principal investigator from the Moi University, School of Medicine, department of Child Health and Paediatrics, Postgraduate programme.

Dr. BENARD M. ATEKA                      Mobile Tel. # 0722476420 or email:  
[atekadr@gmail.com](mailto:atekadr@gmail.com)

**Institutional Review Board:** This research is approved by the Institutional Research and Ethics Committee (IREC) of Moi University/Moi Teaching and Referral Hospital. You may contact IREC in case of questions, complaints or concerns which you feel you cannot discuss with the investigator. Use the following contact: The Chairman IREC, Moi Teaching and Referral Hospital, PO BOX 3-30100, Eldoret, Kenya. Tel. 33471/2/3

**Voluntary Participation:** Refusal to participate will involve no penalty or loss of benefits to which your child is otherwise entitled. Furthermore, the decision to withdraw from this research at any stage after recruitment will not affect your relationship with the investigators or the staff.

**Right of investigator to withdraw:** The investigator reserves the right withdraw your baby from the research without your approval.

**Costs and Compensation to the participants:** Participation in this study is free of any charge. There will be no extra cost or compensation for taking part in this study.

**Number of Participants:** 141 babies in total will be recruited to participate in this study

**Authorization for use of your protected health information:** This study that does not entail the use of your baby's protected health information. We truly appreciate your help and thank you for your baby's participation.

**CONSENT:** By signing this consent form, I confirm that I have read the information herein and that I have been explained well regarding the study. I will be given a signed copy of this consent form for my retention. I voluntarily agree to take part in this study.

Name (parent).....Sign/thumbprint.....Date.....

Name of Investigator .....Signature.....Date.....

**APPENDIX II: DATA COLLECTION TOOL****DEMOGRAPHIC DATA**    Serial #.....**INFANT CHARACTERISTICS**

1. Gender: Male          Female
2. Date of birth \_\_\_\_\_ County of Residence: \_\_\_\_\_  
village \_\_\_\_\_
3. Birth order \_\_\_\_\_
4. Place of birth (circle one): RMBH-LW    RMBH Theatre    other Health  
Facility    at Home  
On the way to hospital (specify site) \_\_\_\_\_
5. Gestational age: by LMP \_\_\_\_\_ Wks;    by U/S \_\_\_\_\_ Wks;    by Ballard  
Scoring \_\_\_\_\_
6. Mode of delivery    SVD \_\_\_\_\_ SBD \_\_\_\_\_ AVD \_\_\_\_\_  
EMCS \_\_\_\_\_ ELCS \_\_\_\_\_
7. Was it a difficult delivery? Yes \_\_\_\_\_ No \_\_\_\_\_
8. Birth weight in grams \_\_\_\_\_
9. Age at admission (hospitalization) \_\_\_\_\_ hrs/days
10. Apgar Score at    1min \_\_\_\_\_ 5min \_\_\_\_\_ 10min \_\_\_\_\_ Cried  
immediately > birth Y or N
11. Diagnosis at admission  
\_\_\_\_\_  
Final  
  
diagnosis \_\_\_\_\_  
  
Evidence of fetal distress during labour: YES \_\_\_\_\_ NO \_\_\_\_\_
12. Age at earliest suspicion of sepsis (onset of  
symptoms) \_\_\_\_\_ Days/Hrs
13. Central venous catheter Y          N
14. Invasive medical or surgical procedures Y    N  
Specify \_\_\_\_\_
15. Nasal catheterization Y          N
16. CPAP use Y          N
17. H2 Receptor blocker or PPI  
use \_\_\_\_\_
18. GIT pathology Y    N          specify \_\_\_\_\_



**CULTURE REPORT**

<u>DATE</u>	<u>SPECIMEN</u>	<u>ORGANISMS</u>	<u>SENSITIVITY*</u>

\* Use space overleaf

**MATERNAL CHARACTERISTICS**

1. Age: \_\_\_\_ years
2. Education level (circle one): None    Primary    secondary    tertiary
3. Socio-Economic status: Unemployed:    Formal Employment    Informal Employment
4. Parity: Para \_\_\_\_ + \_\_\_\_    Number dead.....
5. Total ANC attendance \_\_\_\_\_    Gestational age at first ANC visit \_\_\_\_\_
6. ANC profile: VDRL \_\_\_\_\_    HIV \_\_\_\_\_    DATE HAART COMMENCED \_\_\_\_\_  
HB \_\_\_\_\_  
Urinalysis report if available  
.....
7. Anti-malarial prophylaxis.....
8. Folic acid given .....
9. Ferrous sulphate or other hematinic given .....
10. Did the mother receive intrapartum antibiotic prophylaxis (IPAP)    YES  
NO
11. Antibiotic use during this pregnancy: Y\_\_ or N\_\_ name of the antibiotic \_\_\_\_\_
12. Any other drugs.....
13. Antenatal Complications: List and specify time.....
14. Duration of Labor 1<sup>st</sup> stage \_\_\_\_\_ 2<sup>nd</sup> stage \_\_\_\_\_
15. Rupture of membranes (hrs before delivery) \_\_\_\_\_
16. Number of vaginal examinations performed during labor.....
17. Intrapartum pyrexia: Y\_\_ N\_\_    Highest body Temp \_\_\_\_\_ °C
18. Other illnesses.....
19. PV discharge: Yes \_\_ or No\_\_
  - a. If yes:
    - i. Foul Smelling
    - ii. Not Foul Smelling
    - iii. No Smell
20. UTI during this pregnancy    Y \_\_\_\_ N \_\_\_\_    If yes, Specify date \_\_\_\_\_
21. Was this mother treated for UTI    YES \_\_\_\_    NO \_\_\_\_

### APPENDIX III: ETHICAL APPROVAL



MOI TEACHING AND REFERRAL HOSPITAL  
P.O. BOX 3  
ELDORET  
Tel: 334711/2/3  
Reference: IREC/2014/158  
**Approval Number: 0001264**

#### INSTITUTIONAL RESEARCH AND ETHICS COMMITTEE (IREC)



MOI UNIVERSITY  
SCHOOL OF MEDICINE  
P.O. BOX 4606  
ELDORET  
15<sup>th</sup> September, 2014

Dr. Benard Mageto,  
Moi University,  
School of Medicine,  
P.O. Box 4606-30100,  
**ELDORET-KENYA.**

Dear Dr. Mageto,



#### RE: FORMAL APPROVAL

The Institutional Research and Ethics Committee has reviewed your research proposal titled:-

***"Causative Organisms, Antibiotic Sensitivity Pattern and Risk Factors Associated with Neonatal Sepsis at Moi Teaching and Referral Hospital."***

Your proposal has been granted a Formal Approval Number: **FAN: IREC 1264** on 15<sup>th</sup> September, 2014. You are therefore permitted to begin your investigations.

Note that this approval is for 1 year; it will thus expire on 14<sup>th</sup> September, 2015. If it is necessary to continue with this research beyond the expiry date, a request for continuation should be made in writing to IREC Secretariat two months prior to the expiry date.

You are required to submit progress report(s) regularly as dictated by your proposal. Furthermore, you must notify the Committee of any proposal change (s) or amendment (s), serious or unexpected outcomes related to the conduct of the study, or study termination for any reason. The Committee expects to receive a final report at the end of the study.

Sincerely,

**PROF. E. WERE**  
**CHAIRMAN**  
**INSTITUTIONAL RESEARCH AND ETHICS COMMITTEE**

cc    Director - MTRH            Dean - SOP            Dean - SOM  
      Principal - CHS            Dean - SON            Dean - SOD

## APPENDIX IV: HOSPITAL APPROVAL (MTRH)



### MOI TEACHING AND REFERRAL HOSPITAL

Telephone: 2033471/2/3/4  
 Fax: 61749  
 Email: director@mtrh.or.ke

P. O. Box 3  
 ELDORET

Ref: ELD/MTRH/R.6/VOL.II/2008  
 Dr. Benard Mageto,  
 Moi University,  
 College of Health Sciences,  
 School of Medicine.  
 P.O. Box 4606-30100,  
ELDORET-KENYA.


16<sup>th</sup> September, 2014

**RE: APPROVAL TO CONDUCT RESEARCH AT MTRH**

Upon obtaining approval from the Institutional Research and Ethics Committee (IREC) to conduct your research proposal titled:

***"Causative Organisms, Antibiotic Sensitivity Pattern and Risk Factors Associated with Neonatal Sepsis at Moi Teaching and Referral Hospital"***.

You are hereby permitted to commence your investigation at Moi Teaching and Referral Hospital.

  
**DR. JOHN KIBOSIA**  
**DIRECTOR**  
**MOI TEACHING AND REFERRAL HOSPITAL**

CC - Deputy Director (CS)  
 - Chief Nurse  
 - HOD, HRISM

